Gilead Secures Approvals for Arcellx Acquisition Deal
FOSTER CITY, Calif., April 17, 2026 Gilead Sciences, Inc. has announced that it has obtained all required regulatory approvals...
Alzheimer’s Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy cGxP Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP GMP compliance Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
FOSTER CITY, Calif., April 17, 2026 Gilead Sciences, Inc. has announced that it has obtained all required regulatory approvals...
February 24, 2026 — Foster City, CA & Redwood City, CA:Gilead Sciences, Inc. (Nasdaq: GILD) today revealed a definitive...
